244 related articles for article (PubMed ID: 28692028)
41. Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal B; Vesole DH; Hari PN
Bone Marrow Transplant; 2016 Apr; 51(4):492-500. PubMed ID: 26726943
[TBL] [Abstract][Full Text] [Related]
42. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
[TBL] [Abstract][Full Text] [Related]
43. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.
Rosiñol L; Jiménez R; Rovira M; Martínez C; Fernández-Avilés F; Marín P; Suárez-Lledó M; Gutiérrez-García G; Fernández de Larrea C; Carreras E; Urbano-Ispizua A; Bladé J
Bone Marrow Transplant; 2015 May; 50(5):658-62. PubMed ID: 25621810
[TBL] [Abstract][Full Text] [Related]
45. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
[TBL] [Abstract][Full Text] [Related]
46. A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Bensinger WI; Green DJ; Burwick N; Becker PS
Bone Marrow Transplant; 2014 Apr; 49(4):492-5. PubMed ID: 24419523
[TBL] [Abstract][Full Text] [Related]
47. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.
Yano S; Mori T; Kanda Y; Kato J; Nakaseko C; Fujisawa S; Tomita N; Sakai R; Shono K; Saitoh T; Aotsuka N; Kobayashi N; Saito T; Takahashi S; Kanamori H; Okamoto S;
Bone Marrow Transplant; 2015 Oct; 50(10):1299-305. PubMed ID: 26168068
[TBL] [Abstract][Full Text] [Related]
48. Strategies to improve the outcome of stem cell transplantation in multiple myeloma.
Catley L; Anderson K
Hematol J; 2004; 5(1):9-23. PubMed ID: 14745425
[TBL] [Abstract][Full Text] [Related]
49. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
[TBL] [Abstract][Full Text] [Related]
50. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies.
Sureda A; Schmitz N
Ann Hematol; 2003 Jan; 82(1):1-13. PubMed ID: 12574957
[TBL] [Abstract][Full Text] [Related]
51. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.
Karlin L; Arnulf B; Chevret S; Ades L; Robin M; De Latour RP; Malphettes M; Kabbara N; Asli B; Rocha V; Fermand JP; Socie G
Bone Marrow Transplant; 2011 Feb; 46(2):250-6. PubMed ID: 20400980
[TBL] [Abstract][Full Text] [Related]
52. Isolated orbital relapse of multiple myeloma in a patient with severe chronic GVHD after allogeneic hematopoietic SCT.
Blecha C; Wolff D; Kölbl O; Huber E; Helbig H; Holler B; Holler E; Dietrich-Ntoukas T
Bone Marrow Transplant; 2014 Jul; 49(7):988-9. PubMed ID: 24777190
[No Abstract] [Full Text] [Related]
53. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
54. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
[TBL] [Abstract][Full Text] [Related]
55. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Badros A; Barlogie B; Siegel E; Cottler-Fox M; Zangari M; Fassas A; Morris C; Anaissie E; Van Rhee F; Tricot G
J Clin Oncol; 2002 Mar; 20(5):1295-303. PubMed ID: 11870172
[TBL] [Abstract][Full Text] [Related]
56. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
57. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
[TBL] [Abstract][Full Text] [Related]
58. High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma.
Tuncer HH; Gregory SA; Fung HC
Bone Marrow Transplant; 2011 Aug; 46(8):1156-7. PubMed ID: 20972468
[No Abstract] [Full Text] [Related]
59. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.
Crocchiolo R; Castagna L; Fürst S; El-Cheikh J; Faucher C; Oudin C; Granata A; Bouabdallah R; Coso D; Chabannon C; Balzarotti M; Santoro A; Blaise D
Bone Marrow Transplant; 2013 Feb; 48(2):249-52. PubMed ID: 22732704
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
Patriarca F; Bruno B; Einsele H; Spina F; Giaccone L; Montefusco V; Isola M; Nozzoli C; Nozza A; Morabito F; Corradini P; Fanin R
Biol Blood Marrow Transplant; 2018 Feb; 24(2):406-409. PubMed ID: 29032267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
